PreciseDx is innovating oncology diagnostics, leveraging Artificial Intelligence (AI) for revolutionary, morphology-driven, disease analysis. Combining AI with our patented Morphology Feature Array® (MFA), PreciseDx provides access to unmatched disease insights and accurate, actionable intelligence for more comprehensive decision-making throughout the cancer care continuum.

PreciseBreast™ is an in vitro assessment for early-stage invasive breast cancer that calculates a composite risk of recurrence score based on a proprietary algorithm. PreciseBreast™ leverages AI technology within our Morphology Feature Array® to evaluate the recurrence risk of early-stage breast cancer much faster than traditional testing and with greater reproducibility and precision than any other technology currently utilized in cancer care. PreciseBreast™ is performed on digital scans without the need for tissue specimen or wet lab, and can also use traditional H&E stained slides.